Back to Search
Start Over
COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
- Source :
- Фармакоэкономика, Vol 10, Iss 2, Pp 22-30 (2017)
- Publication Year :
- 2017
- Publisher :
- IRBIS LLC, 2017.
-
Abstract
- The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial clinical effects, these medications have an impact on COPD treatment costs. Minimizing the costs of highly effective medications is necessary to improve the public medical care and drug supply. Objective : to identify the key differences between vilantererol / umeclidinum bromide and olodaterol / tiotropium bromide, and evaluate the ways of minimizing health budget expenditures. Materials and methods . We used the available information from research, clinical trials, and instructions for medical use to conduct a cost analysis that was based on the prices for these medications at different levels of drug supply. As a result, the impact on the healthcare budget was determined under conditions of choosing the least expansive medication and adding vilantererol / umeclidinum bromide in the list of VED. Results . According to the network meta-analysis, when compared with mono-component drugs, vilantererol / umeclidinum bromide showed a more favorable effect on cardiovascular events, as well as a more pronounced effect on the volume of forced exhalation in the first second (FEV1). For the olodaterol / tiotropium bromide combination, no such trend was seen. The costs of 12-month therapy with vilantererol / umeclidinum bromide and with olodaterol / tiotropium bromide were 27,541 and 36,120 rubles, respectively (a difference of 24%). The average direct medical costs were 32,753 and 41,333 rubles per patient per year, respectively. If the vilantererol / umeclidinum bromide combination is added to the VED list and the manufacturer’s maximum selling price is registered at the level of the reference countries, the savings can reach 3-5%. Conclusion . In patients with severe and extremely severe COPD, and also when COPD monotherapy in patients without severe symptoms (FEV1 ≥50%, CAT
- Subjects :
- medicine.medical_specialty
fixed combination
RM1-950
chronic obstructive pulmonary disease
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Bromide
medicine
tiotropium bromide
budget impact analysis
030223 otorhinolaryngology
HB71-74
Pharmacology
cost minimization analysis
COPD
vilantererol
business.industry
laac
olodaterol
Health Policy
Olodaterol
Public Health, Environmental and Occupational Health
cost-effectiveness analysis
copd
Tiotropium bromide
Cost-effectiveness analysis
medicine.disease
Clinical trial
long-acting beta-agonists
Economics as a science
chemistry
umeclidinum bromide
Emergency medicine
Cost-minimization analysis
long-acting anticholinergics
laba
Vilanterol
Therapeutics. Pharmacology
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- Language :
- Russian
- ISSN :
- 20704933 and 20704909
- Volume :
- 10
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Фармакоэкономика
- Accession number :
- edsair.doi.dedup.....68e2b340f150ad9be9f04351c24e2800